299 related articles for article (PubMed ID: 38725856)
21. Aiming for the Sweet Spot: Glyco-Immune Checkpoints and γδ T Cells in Targeted Immunotherapy.
Bartish M; Del Rincón SV; Rudd CE; Saragovi HU
Front Immunol; 2020; 11():564499. PubMed ID: 33133075
[TBL] [Abstract][Full Text] [Related]
22. Immunosuppressive circuits in tumor microenvironment and their influence on cancer treatment efficacy.
Tuccitto A; Shahaj E; Vergani E; Ferro S; Huber V; Rodolfo M; Castelli C; Rivoltini L; Vallacchi V
Virchows Arch; 2019 Apr; 474(4):407-420. PubMed ID: 30374798
[TBL] [Abstract][Full Text] [Related]
23. Improving Breast Cancer Responses to Immunotherapy-a Search for the Achilles Heel of the Tumor Microenvironment.
Jenkins S; Wesolowski R; Gatti-Mays ME
Curr Oncol Rep; 2021 Mar; 23(5):55. PubMed ID: 33755828
[TBL] [Abstract][Full Text] [Related]
24. Tumour associated glycans: A route to boost immunotherapy?
Scott E; Elliott DJ; Munkley J
Clin Chim Acta; 2020 Mar; 502():167-173. PubMed ID: 31870793
[TBL] [Abstract][Full Text] [Related]
25. Harnessing Metabolic Reprogramming to Improve Cancer Immunotherapy.
Yan L; Tan Y; Chen G; Fan J; Zhang J
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638609
[TBL] [Abstract][Full Text] [Related]
26. Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions.
Pansy K; Uhl B; Krstic J; Szmyra M; Fechter K; Santiso A; Thüminger L; Greinix H; Kargl J; Prochazka K; Feichtinger J; Deutsch AJ
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948104
[TBL] [Abstract][Full Text] [Related]
27. NK Cell Metabolism and Tumor Microenvironment.
Terrén I; Orrantia A; Vitallé J; Zenarruzabeitia O; Borrego F
Front Immunol; 2019; 10():2278. PubMed ID: 31616440
[TBL] [Abstract][Full Text] [Related]
28. Aptamers combined with immune checkpoints for cancer detection and targeted therapy: A review.
Li Y; Liu W; Xu H; Zhou Y; Xie W; Guo Y; Liao Z; Jiang X; Liu J; Ren C
Int J Biol Macromol; 2024 Mar; 262(Pt 2):130032. PubMed ID: 38342267
[TBL] [Abstract][Full Text] [Related]
29. CCL21 Programs Immune Activity in Tumor Microenvironment.
Sharma S; Kadam P; Dubinett S
Adv Exp Med Biol; 2020; 1231():67-78. PubMed ID: 32060847
[TBL] [Abstract][Full Text] [Related]
30. Immunometabolism and Its Potential to Improve the Current Limitations of Immunotherapy.
Sheppard AD; Lysaght J
Methods Mol Biol; 2020; 2184():233-263. PubMed ID: 32808230
[TBL] [Abstract][Full Text] [Related]
31. Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors.
Balta E; Wabnitz GH; Samstag Y
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072260
[TBL] [Abstract][Full Text] [Related]
32. Exploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy.
Qiu Q; Lin Y; Ma Y; Li X; Liang J; Chen Z; Liu K; Huang Y; Luo H; Huang R; Luo L
Front Immunol; 2020; 11():612202. PubMed ID: 33488618
[TBL] [Abstract][Full Text] [Related]
33. ILT4 functions as a potential checkpoint molecule for tumor immunotherapy.
Gao A; Sun Y; Peng G
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):278-285. PubMed ID: 29649510
[TBL] [Abstract][Full Text] [Related]
34. Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy.
Wang B; Zhao Q; Zhang Y; Liu Z; Zheng Z; Liu S; Meng L; Xin Y; Jiang X
J Exp Clin Cancer Res; 2021 Jan; 40(1):24. PubMed ID: 33422072
[TBL] [Abstract][Full Text] [Related]
35. Anti-angiogenesis: Opening a new window for immunotherapy.
Guo F; Cui J
Life Sci; 2020 Oct; 258():118163. PubMed ID: 32738363
[TBL] [Abstract][Full Text] [Related]
36. Impacts and mechanisms of metabolic reprogramming of tumor microenvironment for immunotherapy in gastric cancer.
Zhao L; Liu Y; Zhang S; Wei L; Cheng H; Wang J; Wang J
Cell Death Dis; 2022 Apr; 13(4):378. PubMed ID: 35444235
[TBL] [Abstract][Full Text] [Related]
37. Interactions between platelets and the cancer immune microenvironment.
Tuerhong N; Yang Y; Wang C; Huang P; Li Q
Crit Rev Oncol Hematol; 2024 Jul; 199():104380. PubMed ID: 38718939
[TBL] [Abstract][Full Text] [Related]
38. Emerging role of autophagy in anti-tumor immunity: Implications for the modulation of immunotherapy resistance.
Jiang T; Chen X; Ren X; Yang JM; Cheng Y
Drug Resist Updat; 2021 May; 56():100752. PubMed ID: 33765484
[TBL] [Abstract][Full Text] [Related]
39. [Opportunities that improve the effectivity of immunotherapy, bringing targeted therapies into focus].
Maráz A; Varga L; Küronya Z
Magy Onkol; 2019 Sep; 63(3):209-216. PubMed ID: 31533141
[TBL] [Abstract][Full Text] [Related]
40. Long Non-Coding RNAs in the Tumor Immune Microenvironment: Biological Properties and Therapeutic Potential.
Pi YN; Qi WC; Xia BR; Lou G; Jin WL
Front Immunol; 2021; 12():697083. PubMed ID: 34295338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
